Ben Portney

Ben Portney

Bio + Health Investing Team

About

Ben Portney, PhD, is an investing partner on the Bio + Health team. He is a scientist and entrepreneur with a focus on investing in early stage companies building platforms for novel therapeutic discovery and development. He is involved with companies including: Orbital Therapeutics, insitro, BigHat Biosciences, Rezo Therapeutics, and Octant Bio.

Before joining Andreessen Horowitz, Ben was a Senior Associate at Flagship Pioneering, where he worked as part of a venture-creation team to found and grow several biotechnology companies. Prior to Flagship, Ben received his PhD in Biochemistry and Molecular Biology from the University of Maryland, Baltimore, studying the role of epigenetics in cancer plasticity. His graduate work resulted in publication in multiple peer-reviewed journals and several pending patents.

Ben holds a PhD in Biochemistry and Molecular Biology from the University of Maryland, Baltimore and a BS in Biology from the University of Maryland, College Park. He is a proud native of Baltimore and passionately believes that the Wire is the best TV Series of all time.

Latest Content by Ben

Bio + Health

Gate Unveiling with Jordi Mata-Fink

Vineeta Agarwala, Jordi Mata-Fink, Ben Portney, Kris Tatiossian, and Olivia Webb
Bio + Health

Outclassed: The Battle for Therapeutic Market Share

Ben Portney, Adela Tomsejova, and Jorge Conde

Want More Bio+Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Sign Up On Substack